Boston Scientific Corporation
BSX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $5 | $5 |
| % Growth | 0.1% | 8.5% | 2.2% | – |
| Cost of Goods Sold | $2 | $2 | $2 | $2 |
| Gross Profit | $4 | $3 | $3 | $3 |
| % Margin | 69.9% | 67.7% | 63.3% | 58.6% |
| R&D Expenses | $1 | $1 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2 | $2 | $2 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2 | $3 | $2 | $2 |
| Operating Income | $1 | $1 | $1 | $1 |
| % Margin | 20.7% | 16.2% | 19.2% | 12.9% |
| Other Income/Exp. Net | -$0 | $0 | -$0 | -$0 |
| Pre-Tax Income | $1 | $1 | $1 | $1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $1 | $1 | $1 | $1 |
| % Margin | 14.9% | 15.7% | 14.5% | 12.4% |
| EPS | 0.51 | 0.54 | 0.456 | 0.384 |
| % Growth | -5.6% | 18.3% | 18.9% | – |
| EPS Diluted | 0.5 | 0.53 | 0.451 | 0.38 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | $1 | $1 | $1 |
| % Margin | 20.3% | 27% | 26.1% | 23.5% |